BioCentury
ARTICLE | Clinical News

CD101 IV: Phase I data

January 18, 2016 8:00 AM UTC

A double-blind, placebo-controlled, U.S. Phase I trial in 24 healthy volunteers showed that multiple doses of 100, 200 and 400 mg CD101 IV were well tolerated with no serious or severe adverse events ...